ClinicalTrials.gg
RecruitingNCT07082686Updated Jul 23, 2026

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

A Phase 2 interventional study of ICP-248 in Relapsed or Refractory Mantle Cell Lymphoma (MCL), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Primary conditionLymphoma, Mantle-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Mantle-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Planned enrollment
35th of 91
75 · median 50
Started
2025
with 13 others
Phase 2
31 of 98
19 open now
Primary completion
2027-12
later than 30 of 55 live
Registered
82nd of 98
by date
Lead sponsor
4 of 98
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 35th largest by planned enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2025, is one of 31 in phase 2, reaches primary completion later than 30 of the 55 other live ones, and was the 82nd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.

03

Conditions studied

  • Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Browse trials for

04

In context

Lymphoma, Mantle-Cell Reclassified

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

This study's planned enrollment of 75 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years old.
  • Histopathologically confirmed MCL expressing Cyclin D1 and/or t (11;14) chromosomal translocation.Formalin-fixed paraffin-embedded (FFPE) tissues or sections for diagnosis must be provided. It is for the approval of pathological diagnosis by the central pathology laboratory.
  • The patient was diagnosed with mantle cell lymphoma, and the previous treatment needs to meet the following requirements:

    • Failure of at least one adequate prior line of anti-CD20-containing therapy;
    • Failure of at least one adequate prior line of BTK inhibitor (BTKi)-containing therapy.
  • Failure of the last .
  • At least one according to the Lugano 2014 criteria,.
  • performance status of 0-2 .

Exclusion criteria

Exclusion Criteria

  • Current or prior history of central nervous system (CNS) lymphoma.
  • Prior use of BCL-2 inhibitors (e.g., venetoclax/ABT-199, etc.).
  • stem cell transplantation or cellular therapy within 3 months prior to the first dose of ICP-248.
  • Prior allogeneic hematopoietic stem cell transplantation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    ICP-248Tablets

    Drug: ICP-248

Interventions

  • Eligible patients will receive ICP-248 orally as per the protocol

07

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) according to Lugano 2014 assessed by the independent review committee (IRC)

    Time frame: 3 years

Secondary outcomes

  1. According to Lugano 2014: IRC and investigator assessed complete response rate (CRR)

    Time frame: 3 years

  2. Investigator-assessed ORR

    Time frame: 3 years

  3. According to Lugano 2014: IRC and investigator assessed disease control rate (DCR).

    Time frame: 3 years

  4. According to Lugano 2014: IRC and investigator assessed duration of response (DOR).

    Time frame: 3 years

  5. According to Lugano 2014: IRC and investigator assessed time to initial response (TTR).

    Time frame: 3 years

  6. According to Lugano 2014: IRC and investigator assessed progression-free survival (PFS) .

    Time frame: 3 years

  7. Overall survival (OS)

    Time frame: 3 years

  8. Adverse event (AE) assessed according to CTCAE v5.0 criteria

    Time frame: 3 years

  9. Functional Assessment Of Cancer Therapy-Lymphoma (Fact-Lym) and European Quality Of Life Five Dimension Five Level Scale Questionnaire (Eq-5D-5L).

    Time frame: 3 years

  10. Area under the plasma concentration versus time curve (AUC)

    Time frame: 3 years

  11. minimal residual disease (MRD) status

    Time frame: 3 years

  12. Peak Plasma Concentration (Cmax)

    Time frame: 3 years

  13. Time of maximum observed plasma(Tmax)

    Time frame: 3 years

  14. Trough concentration(Ctrough)

    Time frame: 3 years

  15. Apparent clearance (CL/F)

    Time frame: 3 years

08

Study locations

29 of 29 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 28 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 24, 2025
StartActual
Aug 21, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07082686
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Aug 21, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 23, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesutoclax

Start the discussion